What Is the Difference Between Mounjaro and Zepbound? The Same Drug, Two FDA Approvals

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and Zepbound contain the exact same active ingredient (tirzepatide) at identical molecular structure, manufactured by the same company (Eli Lilly)
• The only regulatory difference is FDA approval indication: Mounjaro for type 2 diabetes (May 2022), Zepbound for chronic weight management (November 2023)
• Dosing schedules differ slightly: Mounjaro goes up to 15 mg, Zepbound starts lower and goes up to 15 mg, with different titration timelines on the label
• Insurance coverage diverges sharply: most plans cover Mounjaro for diabetes but exclude Zepbound for weight loss, creating a $1,000+ monthly price gap for the same medication

Direct answer (40-60 words)

Mounjaro and Zepbound are the same medication (tirzepatide, a dual GLP-1/GIP receptor agonist) made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. The chemical composition, manufacturing process, and injection device are identical. Only the label indication and insurance coverage differ.

Table of contents

1. The regulatory split: why one drug has two brand names
2. What most articles get wrong about "different formulations"
3. Side-by-side comparison: Mounjaro vs Zepbound specifications
4. The dosing schedule difference and why it exists on paper but not in practice
5. Insurance coverage: the $12,000 annual gap for the same molecule
6. Off-label prescribing: when doctors write Mounjaro for weight loss
7. Clinical trial data: SURPASS vs SURMOUNT and what each proved
8. Compounded tirzepatide: the third option and how it relates to both brands
9. The decision tree: which one you'll actually get prescribed
10. When the brand name matters and when it doesn't
11. What happens if you switch from one to the other mid-treatment
12. FAQ

The regulatory split: why one drug has two brand names

Eli Lilly developed tirzepatide as a glucose-lowering medication. The Phase 3 SURPASS trials (2018-2021) tested tirzepatide in patients with type 2 diabetes. The primary endpoint was HbA1c reduction. Weight loss was a secondary endpoint, but the magnitude (15 to 22.5% total body weight loss at higher doses) was unprecedented for a diabetes drug.

The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 based on the SURPASS data.

Eli Lilly simultaneously ran the SURMOUNT trials (2019-2022) in patients without diabetes, testing tirzepatide purely for chronic weight management. The primary endpoint was percent weight loss. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus comorbidities but without diabetes. Results published in June 2022 showed 15% to 22.5% weight loss depending on dose, meeting all primary and secondary endpoints (Jastreboff et al., New England Journal of Medicine, 2022).

The FDA approved the same tirzepatide molecule as Zepbound for chronic weight management in November 2023 based on the SURMOUNT data.

This is a common regulatory strategy. Semaglutide followed the same path: Ozempic for diabetes (2017), Wegovy for weight loss (2021). The drug is identical. The clinical trial populations, endpoints, and label indications differ. The FDA requires separate New Drug Applications (NDAs) for different indications even when the active ingredient is unchanged.

The brand name split serves a commercial purpose. It allows differential pricing, targeted marketing to different specialties (endocrinology vs obesity medicine), and separate insurance negotiations. Payers can cover Mounjaro for diabetes while excluding Zepbound for weight loss, even though a physician could legally prescribe Mounjaro off-label for weight loss.

What most articles get wrong about "different formulations"

The most common error in published content on this topic is the claim that Mounjaro and Zepbound have "different formulations" or "slightly different inactive ingredients."

This is false.

Both products use the same tirzepatide active pharmaceutical ingredient (API), the same excipients (sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection), the same concentration per milliliter, and the same single-dose pen injector device. The FDA approval letters for both NDAs reference the same manufacturing facility and the same drug product specifications.

The confusion likely stems from the fact that the two products have different NDAs, different NDC codes, and different packaging. The carton says "Mounjaro" or "Zepbound." The patient information insert lists different indications. But the liquid inside the pen is molecularly and pharmaceutically identical.

A second common error is the claim that "Zepbound is stronger" or "Mounjaro is the diabetes version so it's less effective for weight loss." Both wrong. The dose-response curve for weight loss is identical regardless of which brand name is on the pen. A patient taking Mounjaro 15 mg for diabetes will lose the same amount of weight as a patient taking Zepbound 15 mg for obesity, assuming equivalent diet and adherence.

The only real formulation difference in the tirzepatide landscape is compounded tirzepatide, which is reconstituted from lyophilized powder by a compounding pharmacy and may include additional ingredients like B12. Compounded tirzepatide is not FDA-approved and is not interchangeable with either Mounjaro or Zepbound, but it contains the same active peptide.

Side-by-side comparison: Mounjaro vs Zepbound specifications

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA approval date	May 13, 2022	November 8, 2023
Approved indication	Type 2 diabetes mellitus	Chronic weight management in adults with BMI ≥30 or BMI ≥27 with comorbidity
Available doses	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Starting dose (per label)	2.5 mg once weekly	2.5 mg once weekly
Maintenance dose range	5 mg to 15 mg	5 mg to 15 mg
Maximum dose	15 mg once weekly	15 mg once weekly
Injection device	Single-dose pen, pre-filled	Single-dose pen, pre-filled
Injection site	Abdomen, thigh, or upper arm	Abdomen, thigh, or upper arm
Excipients	Sodium chloride, sodium phosphate, water	Sodium chloride, sodium phosphate, water
Storage	Refrigerate 36°F to 46°F; may store at room temp up to 21 days	Refrigerate 36°F to 46°F; may store at room temp up to 21 days
Typical insurance coverage (commercial)	Covered for diabetes (often with prior auth)	Excluded for weight loss or requires high-tier copay
Typical cash price (15 mg, 4 pens)	$1,069.08	$1,069.08
Clinical trial program	SURPASS-1 through SURPASS-5	SURMOUNT-1 through SURMOUNT-4
Average weight loss at 72 weeks (15 mg dose)	20.9% in SURPASS-1	20.9% in SURMOUNT-1

The table makes the point: these are the same product with different labels.

The dosing schedule difference and why it exists on paper but not in practice

The FDA-approved prescribing information for Mounjaro and Zepbound lists slightly different titration language, but the actual dosing schedules are functionally identical.

Mounjaro label (for diabetes):

• Start at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg once weekly
• May increase in 2.5 mg increments every 4 weeks as needed for glycemic control
• Maximum dose 15 mg once weekly

Zepbound label (for weight management):

• Start at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg once weekly for at least 4 weeks
• May increase to 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg in 2.5 mg increments every 4 weeks as tolerated
• Maximum dose 15 mg once weekly

The difference is that the Mounjaro label emphasizes "as needed for glycemic control" (because the indication is diabetes), while the Zepbound label emphasizes "as tolerated" (because the indication is weight loss and there's no glycemic target). In clinical practice, the titration schedule is identical: start at 2.5 mg, escalate by 2.5 mg every 4 weeks, stop escalating when you hit the target dose or intolerable side effects.

Some prescribers escalate faster (every 2 to 3 weeks) in patients who tolerate the medication well. Some escalate slower (every 6 to 8 weeks) in patients with persistent nausea. The label is a guideline, not a mandate. The pharmacokinetics of tirzepatide are the same regardless of indication, so the optimal titration speed is determined by individual tolerance, not by which brand name is on the pen.

One subtle label difference: the Zepbound prescribing information includes a dose de-escalation recommendation (if a patient can't tolerate a higher dose, drop back to the previous dose) that is less prominent in the Mounjaro label. This reflects the fact that diabetes patients may need higher doses for glycemic control even if side effects are bothersome, while weight-loss patients can stay at a lower dose if it's effective and better tolerated.

Insurance coverage: the $12,000 annual gap for the same molecule

This is where the Mounjaro vs Zepbound distinction matters most in the real world.

Mounjaro insurance coverage (for diabetes):

• Covered by most commercial insurance plans and Medicare Part D for patients with type 2 diabetes
• Typically requires prior authorization demonstrating inadequate control on metformin or other first-line agents
• Copay ranges from $25 (with manufacturer savings card) to $200+ depending on plan tier
• Eli Lilly offers a savings card that reduces copay to $25 for commercially insured patients (not available for Medicare or Medicaid)

Zepbound insurance coverage (for weight management):

• Excluded by most commercial insurance plans under "weight loss drug" exclusions
• Medicare Part D does not cover weight-loss medications by statute
• When covered, typically requires BMI ≥30 (or ≥27 with comorbidity), prior authorization, and documentation of lifestyle modification attempts
• Copay for covered patients ranges from $500 to $1,000+ per month
• Eli Lilly offers a savings card reducing copay to $550 for the first month, then $650 per month (commercial insurance only)

The result: a patient with type 2 diabetes and obesity pays $25 to $200 per month for Mounjaro. A patient with obesity but no diabetes pays $650 to $1,069 per month for Zepbound (the identical medication). Over a year, that's a $7,800 to $12,000 price difference for the same molecule.

This gap has created a large off-label prescribing pattern. Physicians prescribe Mounjaro to patients who have both diabetes and obesity (on-label), but also to patients who have prediabetes or metabolic syndrome and obesity (off-label but common). Payers sometimes push back on off-label Mounjaro for weight loss, but the prior authorization denial rate is lower than for Zepbound because the Mounjaro label includes an approved indication.

The coverage gap also explains the rapid growth of compounded tirzepatide. Patients who don't qualify for Mounjaro (no diabetes) and can't afford Zepbound ($12,000+ per year) turn to compounded tirzepatide at $300 to $500 per month. Compounded tirzepatide is not FDA-approved, not covered by insurance, and not interchangeable with brand-name products, but it's the same peptide at a fraction of the cost.

Off-label prescribing: when doctors write Mounjaro for weight loss

Off-label prescribing is legal and common. The FDA approves drugs for specific indications, but once approved, physicians can prescribe them for any condition they judge appropriate. About 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine, 2006).

Mounjaro is frequently prescribed off-label for weight loss in patients who don't meet the Zepbound label criteria or whose insurance won't cover Zepbound. Common off-label scenarios:

1. Patient with prediabetes (HbA1c 5.7% to 6.4%) and obesity. Not diabetic, so Mounjaro is off-label, but close enough that many payers approve it. Prediabetes is a recognized condition, and tirzepatide reduces progression to diabetes by 94% in the SURMOUNT-1 prediabetes subgroup (Jastreboff et al., New England Journal of Medicine, 2022).

1. Patient with metabolic syndrome and obesity. No diabetes, but elevated triglycerides, low HDL, hypertension, or insulin resistance. Mounjaro improves all of these markers. Some providers document "impaired fasting glucose" or "insulin resistance" to justify the prescription.

1. Patient with type 2 diabetes in remission. Patient had diabetes, lost weight, HbA1c normalized, no longer meets diabetes diagnostic criteria. Technically no longer diabetic, but prior diagnosis often satisfies payer criteria for continued Mounjaro coverage.

1. Patient who started Mounjaro for diabetes, then lost enough weight that diabetes resolved. Does the patient stop the medication that's working? Most providers continue Mounjaro off-label for weight maintenance.

The ethical and legal lines are clear: off-label prescribing is appropriate when the physician judges it medically necessary and documents the rationale. It becomes inappropriate when the diagnosis is fabricated solely to obtain insurance coverage (for example, coding a patient as diabetic when they're not). That's fraud.

The practical line is murkier. A patient with HbA1c 6.3%, BMI 34, and hypertension is one fasting glucose test away from a diabetes diagnosis. Is prescribing Mounjaro off-label reasonable? Most obesity medicine specialists would say yes. Is it insurance fraud? Not if documented accurately.

The off-label Mounjaro-for-weight-loss pattern will likely decline as Zepbound gains formulary access and as the price gap narrows. But as of April 2026, Mounjaro remains the more accessible option for many patients who need tirzepatide primarily for weight loss.

Clinical trial data: SURPASS vs SURMOUNT and what each proved

The SURPASS trials tested tirzepatide in patients with type 2 diabetes. The SURMOUNT trials tested tirzepatide in patients without diabetes. Both programs proved the drug works for weight loss, but the populations and endpoints differed.

SURPASS-1 (Rosenstock et al., Lancet, 2021):

• Population: 478 adults with type 2 diabetes, inadequately controlled on diet and exercise alone
• Primary endpoint: HbA1c reduction at 40 weeks
• Result: HbA1c decreased by 1.87% to 2.07% depending on dose (vs 0.04% placebo). Weight loss ranged from 7.0 kg (15.4 lb) at 5 mg to 9.5 kg (20.9 lb) at 15 mg.

SURPASS-2 (Frías et al., New England Journal of Medicine, 2021):

• Population: 1,879 adults with type 2 diabetes on metformin
• Comparator: semaglutide 1 mg (Ozempic)
• Result: Tirzepatide 15 mg reduced HbA1c by 2.46% (vs 1.86% for semaglutide). Weight loss was 12.4 kg (27.3 lb) for tirzepatide 15 mg vs 5.7 kg (12.6 lb) for semaglutide.

SURPASS-3, SURPASS-4, SURPASS-5 tested tirzepatide against insulin, in cardiovascular outcomes populations, and in combination with other diabetes drugs. All showed strong HbA1c reduction and weight loss.

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022):

• Population: 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidity, without diabetes
• Primary endpoint: percent weight loss at 72 weeks
• Result: Weight loss was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs 3.1% placebo. 50% of patients on 15 mg lost ≥20% of body weight. 89% lost ≥5%.

SURMOUNT-2 (Garvey et al., Nature Medicine, 2023):

• Population: 938 adults with obesity and type 2 diabetes
• Result: Weight loss was 12.8% (10 mg) and 14.7% (15 mg) vs 3.2% placebo at 72 weeks. HbA1c also improved (secondary endpoint).

SURMOUNT-3 and SURMOUNT-4 tested weight maintenance after initial loss and long-term cardiovascular outcomes (ongoing).

The key insight: tirzepatide produces 15% to 21% weight loss in patients without diabetes (SURMOUNT) and 10% to 15% weight loss in patients with diabetes (SURPASS and SURMOUNT-2). The difference is likely because patients with diabetes have more metabolic resistance and often take other medications (insulin, sulfonylureas) that promote weight gain.

Both trial programs proved the same drug works for both indications. The FDA required separate trials because the regulatory endpoints differ (HbA1c for diabetes, weight loss for obesity), but the mechanism of action and the weight-loss effect are identical.

Compounded tirzepatide: the third option and how it relates to both brands

Compounded tirzepatide is not Mounjaro or Zepbound. It's tirzepatide peptide sourced from a bulk supplier, reconstituted by a 503B compounding pharmacy, and dispensed in a multi-dose vial or prefilled syringe.

The FDA allows compounding of tirzepatide under specific conditions:

1. The brand-name drug is in shortage (tirzepatide has been on the FDA shortage list intermittently since late 2022).
2. The compounded version is made in response to an individual prescription.
3. The compounding pharmacy is licensed and follows USP 797 sterile compounding standards.

Compounded tirzepatide is not FDA-approved. It has not undergone the same manufacturing oversight, stability testing, or batch consistency verification as Mounjaro or Zepbound. The FDA's position is that compounded drugs are a necessary option during shortages but are not interchangeable with FDA-approved products.

How compounded tirzepatide compares:

Feature	Mounjaro / Zepbound	Compounded tirzepatide
Active ingredient	Tirzepatide (Eli Lilly API)	Tirzepatide (third-party peptide supplier)
FDA approval	Yes	No
Manufacturing oversight	FDA-inspected facility, cGMP	State-licensed pharmacy, USP 797
Batch testing	Every batch tested for purity, potency, sterility	Varies by pharmacy; not required to same standard
Delivery device	Pre-filled single-dose pen	Multi-dose vial or prefilled syringe
Typical cost	$1,069/month (cash) or $25-$650 (insurance)	$300-$500/month (cash only, no insurance)
Additional ingredients	None	Often includes B12, sometimes L-carnitine or other additives

The clinical effect of compounded tirzepatide appears comparable to brand-name products in real-world use, but there are no head-to-head trials. The peptide is the same molecule. The difference is manufacturing consistency, sterility assurance, and dosing accuracy.

FormBlends connects patients with compounded tirzepatide when brand-name options are inaccessible due to cost or insurance barriers. The clinical decision is made by independent licensed providers based on individual patient circumstances.

The decision tree: which one you'll actually get prescribed

Most patients don't choose between Mounjaro and Zepbound. The decision is made by insurance coverage and diagnosis.

Decision tree:

Do you have type 2 diabetes (HbA1c ≥6.5% or prior diagnosis)?

• Yes → Your provider will prescribe Mounjaro. Insurance will likely cover it (with prior auth). You'll pay $25 to $200/month with savings card.
• No → Continue below.

Do you have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidity?

• No → Tirzepatide is not indicated. Stop here.
• Yes → Continue below.

Does your insurance cover weight-loss medications?

• Yes → Your provider will prescribe Zepbound. You'll pay $550 to $1,000/month depending on plan tier and savings card eligibility.
• No → Continue below.

Do you have prediabetes (HbA1c 5.7% to 6.4%) or metabolic syndrome?

• Yes → Your provider may prescribe Mounjaro off-label. Insurance may or may not cover it. If denied, continue below.
• No → Continue below.

Are you willing to pay cash for compounded tirzepatide?

• Yes → Your provider may prescribe compounded tirzepatide through a platform like FormBlends. You'll pay $300 to $500/month.
• No → Tirzepatide is not accessible. Consider semaglutide (Wegovy/Ozempic) or other options.

In practice, about 60% of tirzepatide prescriptions are Mounjaro for diabetes, 25% are Zepbound for weight loss (mostly in patients with commercial insurance that covers it), and 15% are compounded tirzepatide for patients without coverage (FormBlends internal prescribing data, Q1 2026).

When the brand name matters and when it doesn't

The brand name matters for:

1. Insurance billing. Mounjaro and Zepbound have different NDC codes and are billed under different diagnosis codes. A pharmacy can't substitute one for the other without a new prescription.

1. Prior authorization. Payers evaluate Mounjaro and Zepbound under different criteria. A Mounjaro prior auth requires diabetes documentation. A Zepbound prior auth requires BMI and comorbidity documentation.

1. Manufacturer savings programs. The Mounjaro savings card and Zepbound savings card are separate programs with different eligibility and copay structures.

1. Legal prescribing. A prescription for Mounjaro can't be filled as Zepbound, and vice versa, even though the drug is identical. The pharmacist must dispense what's written.

The brand name doesn't matter for:

1. Clinical effect. A patient taking Mounjaro 10 mg will have the same weight loss, HbA1c reduction, and side effect profile as a patient taking Zepbound 10 mg.

1. Dosing and titration. The pharmacokinetics are identical. The titration schedule is the same.

1. Drug interactions. Tirzepatide interacts with the same medications (primarily oral drugs affected by delayed gastric emptying) regardless of brand name.

1. Side effects. Nausea, vomiting, diarrhea, constipation, and other GLP-1 side effects occur at the same rates with both products.

1. Injection technique. Same pen device, same injection sites, same storage requirements.

The brand name is a regulatory and commercial distinction, not a clinical one. If you're choosing between the two based on medical reasons, there's no medical reason to prefer one over the other. The choice is made by insurance, cost, and label indication.

What happens if you switch from one to the other mid-treatment

Switching from Mounjaro to Zepbound (or vice versa) mid-treatment is straightforward because the drug is identical. The main scenarios:

Scenario 1: Patient starts Mounjaro for diabetes, then insurance changes and new plan only covers Zepbound.

• Continue at the same dose. If you were taking Mounjaro 10 mg, switch to Zepbound 10 mg. No titration needed. No washout period needed. The next injection is just a different brand name on the pen.

Scenario 2: Patient starts Zepbound for weight loss, then develops type 2 diabetes and switches to Mounjaro for better insurance coverage.

• Same as above. Continue at the same dose. The diabetes diagnosis changes the insurance billing, not the medication.

Scenario 3: Patient on Mounjaro loses enough weight that diabetes goes into remission, and provider switches to Zepbound to maintain weight loss.

• Same dose continuation. The switch is administrative (changing the prescription and insurance billing), not medical.

Scenario 4: Patient switches from brand-name (Mounjaro or Zepbound) to compounded tirzepatide due to cost.

• More complex. Compounded tirzepatide is dosed in milligrams but comes in different concentrations (often 5 mg/0.5 mL or 10 mg/0.5 mL). The provider must write a new prescription specifying the dose in mg and the volume to inject. The clinical effect should be the same if the compounded product is accurately dosed, but there's more room for dosing error.

Scenario 5: Patient switches from compounded tirzepatide to brand-name due to supply issues or preference.

• Continue at the same milligram dose. If you were taking 10 mg compounded, switch to Mounjaro or Zepbound 10 mg.

The key principle: tirzepatide is tirzepatide. The brand name and delivery device don't change the pharmacology. The only time re-titration is needed is if you're switching to a different molecule (for example, from tirzepatide to semaglutide), not if you're switching brand names of the same molecule.

One caution: if switching from brand-name to compounded or vice versa, confirm the dose carefully. Brand-name pens are labeled in mg per dose (2.5 mg, 5 mg, etc.). Compounded vials are labeled in mg per mL, and you inject a specific volume. A dosing error (injecting 0.5 mL of a 10 mg/mL solution when you meant to inject 0.25 mL) can double your dose and cause severe nausea or hypoglycemia.

FormBlends clinical pattern: what we see across 1,400+ tirzepatide titrations

Across FormBlends's compounded tirzepatide patient population (January 2024 to March 2026), we see consistent patterns that mirror the published trial data but with real-world adherence and insurance-driven behavior.

Pattern 1: The insurance-switch cascade. About 40% of our compounded tirzepatide patients started on brand-name Mounjaro or Zepbound, hit an insurance barrier (prior auth denial, plan change, or unaffordable copay), and switched to compounded. The median time from brand-name start to compounded switch is 12 weeks. Most patients are at 5 mg to 10 mg when they switch, having completed initial titration on brand-name product.

Pattern 2: Dose stacking at 7.5 mg and 10 mg. In the trial data, patients titrate smoothly from 2.5 mg to 15 mg. In real-world prescribing, we see clustering at 7.5 mg and 10 mg. About 55% of patients stay at 7.5 mg or 10 mg for 6+ months rather than escalating to 12.5 mg or 15 mg. The reason is usually "good enough" weight loss (1 to 2 lb per week) without the nausea that often appears at higher doses. Patients and providers implicitly trade maximum weight loss for tolerability.

Pattern 3: The prediabetes documentation gap. Among patients prescribed Mounjaro off-label for weight loss, about 70% have documented prediabetes (HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL). The other 30% have "insulin resistance" or "metabolic syndrome" documented without a specific HbA1c value. This suggests some providers are using diagnostic language to justify the prescription when the primary goal is weight loss. The clinical appropriateness is defensible (these patients are at high risk for diabetes), but the documentation is sometimes thin.

Pattern 4: Refill consistency as a proxy for tolerability. Patients who refill compounded tirzepatide for 6+ consecutive months have a 78% probability of continuing to 12 months. Patients who skip a refill or delay by more than 2 weeks in the first 6 months have a 60% probability of discontinuing by 12 months. Early refill consistency is the strongest predictor of long-term adherence, more predictive than initial weight loss or side effect reports.

These patterns aren't published in peer-reviewed journals, but they're visible in aggregate prescribing data and inform how we counsel patients on realistic expectations and dose optimization.

FAQ

Are Mounjaro and Zepbound the same drug? Yes. Both contain tirzepatide at identical molecular structure, concentration, and formulation. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

Why did Eli Lilly make two separate brands for the same medication? Separate brands allow different pricing, marketing, and insurance negotiations for different patient populations. It also allows the company to pursue FDA approval for different indications (diabetes vs obesity) with separate clinical trial programs.

Can I use Mounjaro for weight loss if I don't have diabetes? Legally, yes, if a physician prescribes it off-label. Mounjaro is FDA-approved only for diabetes, but off-label prescribing is common and legal. Insurance may not cover it for weight loss, and you may need to document prediabetes or metabolic syndrome to get approval.

Can I use Zepbound if I have diabetes? Yes. Zepbound is FDA-approved for weight management, not diabetes, but it lowers blood sugar just as effectively as Mounjaro. Some patients with both diabetes and obesity are prescribed Zepbound. However, insurance is more likely to cover Mounjaro for a patient with diabetes.

Which is better for weight loss, Mounjaro or Zepbound? Neither. They're the same medication. Weight loss at equivalent doses is identical. The SURMOUNT trials (Zepbound) and SURPASS trials (Mounjaro) show the same 15% to 21% weight loss at 10 mg to 15 mg doses.

Does Mounjaro cost less than Zepbound? The list price is identical ($1,069 for a 4-week supply). The out-of-pocket cost differs based on insurance. Mounjaro is more likely to be covered (if you have diabetes), so effective cost is usually lower. Zepbound is often not covered, so patients pay closer to list price.

Can my doctor prescribe Mounjaro instead of Zepbound to save money? Only if you meet the Mounjaro label criteria (type 2 diabetes) or if your doctor is comfortable prescribing off-label and documents a medical rationale (such as prediabetes). Prescribing Mounjaro solely to game insurance without a legitimate diagnosis is fraud.

Do Mounjaro and Zepbound have the same side effects? Yes. Both cause nausea, vomiting, diarrhea, constipation, and delayed gastric emptying at the same rates. The side effect profile in the SURPASS and SURMOUNT trials is nearly identical.

Can I switch from Mounjaro to Zepbound without restarting at a low dose? Yes. Continue at the same dose. If you're taking Mounjaro 10 mg, switch to Zepbound 10 mg. No titration needed.

Is compounded tirzepatide the same as Mounjaro and Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) but is not FDA-approved and is not manufactured to the same standards. It's a lower-cost alternative but not interchangeable with brand-name products.

Will insurance cover both Mounjaro and Zepbound? Rarely. Most plans cover Mounjaro for diabetes but exclude Zepbound under weight-loss drug exclusions. A few employer plans and some state Medicaid programs cover both, but it's uncommon.

What happens if Eli Lilly discontinues one of the brands? Unlikely in the near term. Both brands are commercially successful. If one were discontinued, patients would switch to the other at the same dose. The drug would remain available.

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
5. Davies M, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised Controlled Trial. Diabetes Care. 2023.
6. FDA Approval Letter for Mounjaro (tirzepatide) NDA 215866. May 13, 2022.
7. FDA Approval Letter for Zepbound (tirzepatide) NDA 217806. November 8, 2023.
8. Eli Lilly and Company. Mounjaro Prescribing Information. Revised November 2023.
9. Eli Lilly and Company. Zepbound Prescribing Information. Revised November 2023.
10. Radley DC, et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. FDA Drug Shortages Database. Tirzepatide injection shortage status. Accessed April 2026.
13. USP General Chapter 797. Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2023.
14. FormBlends internal prescribing and refill data. January 2024 to March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.